Clinical effect of levetiracetam combined with topiramate in the treatment of refractory epilepsy syndrome

Abstract

Objective \nTo observe the clinical effect of levetiracetam combined with topiramate in the treatment of children with Lennox-Gastaut syndrome(LGS). \n \n \nMethods \nFrom January 2016 to August 2018, 60 cases of LGS syndrome admitted to the pediatrics department of Ganzhou People s Hospital were selected The patients were divided into left ethylancetan single drug treatment group, topiramate single drug treatment group, and left ethylancetin combined with topiramate treatment group according to the digital table, with 20 cases in each group.The children in the three groups were treated with the intervention of levetiracetam, topiramate and levetiracetam combined with topiramate according to the test requirements.After 8 weeks of treatment, the clinical efficacy was compared among the three groups in terms of efficacy, cranial magnetic resonance spectrum, eeg slow wave index and intelligence evaluation. \n \n \nResults \nThe clinical effective rate(95%), NAA/Cho+ Cr(0.882±0.107), NAA/Cho(1.624±0.088) and NAA/Cr(1.634±0.042) of the combined treatment group were significantly higher than those before treatment, the differences were statistically significant(all P<0.05). The eeg slow wave index[(9.11±0.63)μV]and sleep period[(18.02±0.66)μV] were significantly lower than those before treatment, and the differences were statistically significant(all P<0.05). The comprehension scores[(15.62±2.55)points], FIQ scores[(106.85±2.64)points]and VIQ scores[(107.28±3.06)points]were significantly higher than those before treatment, the differences were statistically significant(all P<0.05). \n \n \nConclusion \nLevetiracetam combined with topiramate in the treatment of refractory epilepsy syndrome has good curative effect, and is worthy of wide clinical application. \n \n \nKey words: \nLennox-Gastaut syndrome;\xa0Levetiracetam;\xa0Topiramate;\xa0Treatment;\xa0Children